Protocol No. CAMN107AUS37: "Phase II Randomized, Multicenter Study of Treatment-Free Remission in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients Who Achieve and Sustain MR4.5 after Switching to Nilotinib"

Project: Research project

Project Details

StatusFinished
Effective start/end date3/26/13 → 12/31/20

Funding

  • Novartis Pharmaceuticals Corporation ( Award # ): $94,543.00